Aromazin (Exemestane) Therapeutic Uses

Quick Facts

• ​ May be used to support the management of certain forms of early breast cancer.
• ​ Supports treatment for advanced breast cancer in postmenopausal women.

---

Aromazin is indicated for specific treatment regimens concerning breast cancer in women who have completed menopause.

One use is for the adjuvant treatment of early breast cancer that is estrogen-receptor positive. This typically involves postmenopausal women who have initially received a course of tamoxifen therapy (for a period of two to three years) and then transition to Aromazin to complete a total of five consecutive years of hormonal therapy.

Additionally, Aromazin provides an established treatment option for advanced breast cancer in postmenopausal women. This indication applies to cases where the condition has progressed following prior anti-estrogen therapy, such as tamoxifen. The objective of treatment is to manage the progression of the disease. Treatment protocols are determined by a qualified healthcare professional.

Official Eligibility Rules for Aromasin (Exemestane)

The eligibility to use Aromasin is strictly defined by official regulatory documentation, focusing on hormonal status, age, and pre-existing conditions. The medicine is formally established for use only in postmenopausal women.

---

Population Category	Official Eligibility Status
Absolute Contraindications	Premenopausal women, women who are or may become pregnant, and any patient with a known hypersensitivity to the active substance exemestane or any of the product’s excipients.
Use Not Recommended	Children and adolescents (under 18 years), as safety and efficacy have not been established in the pediatric population. Use is also not recommended for women who are lactating.
Conditional Use	Patients with existing hepatic impairment or renal impairment must use the medicine with caution. While no dose adjustments are mandated for these conditions, regulatory labels advise caution due to increased systemic drug exposure.

---

Women of childbearing potential are subject to an official constraint and must use effective non-hormonal contraception during treatment and for a defined period afterward. Eligibility is strictly contingent on a confirmed postmenopausal endocrine status and the absence of any absolute contraindications listed in the official prescribing information.

Interactions with other medicines and products

The interaction profile for Aromazin (exemestane) details specific constraints when used alongside certain other medications or products. Official regulatory documentation highlights two key interaction domains:

• Estrogen-Containing Agents: Aromazin should not be co-administered with any agents containing estrogen, such as hormone replacement therapy or oral contraceptives. This restriction is necessary because estrogen interferes with the intended pharmacologic action of Aromazin.
• Strong CYP 3A4 Inducers: Medications or herbal products classified as strong inducers of the CYP 3A4 enzyme are documented to significantly decrease the systemic exposure to Aromazin. Explicitly listed examples include rifampicin, phenytoin, carbamazepine, phenobarbital, and the herbal product St. John's wort (Hypericum perforatum).

When co-administration with a strong CYP 3A4 inducer is necessary, the official labeling mandates a change in the daily dose of Aromazin to compensate for the reduced drug levels. Formal drug interaction studies have also indicated that potent inhibitors of the CYP 3A4 enzyme do not significantly influence the amount of Aromazin in the body, suggesting a low likelihood of clinically significant interactions in that domain. The regulatory profile is defined by these two mechanisms: pharmacodynamic antagonism by estrogens and pharmacokinetic reduction by enzyme inducers.

Irreversible Inactivation: The Mechanism of Suicide Inhibition

Exemestane acts as a mechanism-based inhibitor, targeting the Aromatase Enzyme (CYP19A1), which is responsible for the final conversion of androgens into estrogens. The drug is chemically altered by the enzyme, which converts it into a reactive intermediate that forms a stable, covalent bond with the active site. This process results in the permanent inactivation of the enzyme molecule, a mechanism known as suicide inhibition, which is irreversible and requires the body to synthesize new enzyme protein to restore function.

Sustained Estrogen Deprivation and Selectivity

The permanent destruction of the aromatase enzyme pool leads to a systemic estrogen deprivation, effectively blocking 85% to 95% of estrogen synthesis in peripheral tissues like fat and muscle. This high-level suppression of the estrogen milieu is sustained because of the irreversible binding. Crucially, the mechanism is highly selective, which results in non-interference with the adrenal steroidogenesis pathway and the biosynthesis of adrenal hormones such as cortisol and aldosterone.

Administration Guidelines

Aromazin (Exemestane) is supplied as a 25 mg film-coated tablet intended for oral administration. The administration protocol is based on a consistent, non-titrated daily regimen to ensure reliable systemic exposure.

Administration Scope	Instruction Summary
Standard Dosing	One 25 mg tablet once daily. This dose is used for both the adjuvant treatment and the advanced setting.
Timing & Food	The tablet is taken after a meal. This condition is specified to optimize the absorption of the medicine.
Dose Modification	A modified dose of 50 mg once daily is utilized when the medicine is taken concurrently with a strong CYP 3A4 inducer, such as rifampicin or phenytoin.
Duration (Adjuvant)	Treatment typically continues until the completion of five consecutive years of total combined hormonal therapy (which includes prior tamoxifen), or until tumor relapse.
Duration (Advanced)	Treatment typically continues until there is evident tumor progression.
Organ Impairment	No dose adjustment is typically required for older adults or for patients with mild-to-moderate renal or hepatic insufficiency.

Handling and Procedural Summary

For consistent use, the tablet is taken at approximately the same time each day. If a dose is missed, that dose is skipped and the normal daily schedule resumes at the next scheduled time. A double dose is not taken to compensate for a missed dose. The medicine is not recommended for use in the pediatric population.

Aromazin: Recent Clinical Evidence

---

Evidence for Use in Early Breast Cancer (Sequential Adjuvant Therapy)

Research for this indication was evaluated in large-scale, international Randomized Controlled Trials (RCTs). These studies compared Aromazin against continuing standard hormonal therapy in postmenopausal women with early-stage, Estrogen-Receptor positive breast cancer who had already received treatment with tamoxifen for a period of two to three years. The main outcomes research examined were long-term clinical measurements, specifically Disease-Free Survival (DFS) and Overall Survival (OS), key measurements in cancer research.

Trials described patterns observed in the studies regarding Disease-Free Survival when comparing the switch to Aromazin versus continuing tamoxifen. These findings describe patterns observed in the studies regarding how the two treatment approaches evolved over the study period. When research examined Aromazin against other similar medicines, comparative studies reported patterns of recurrence-related endpoints that appeared to be comparable in initial upfront treatment scenarios.

Regarding long-term outcomes, certainty remains low surrounding final measurements of Overall Survival in the entire studied population because these endpoints required prolonged observation to mature fully. Limited information for long-term outcomes is available characterizing outcomes over periods extending beyond ten years.

---

Evidence for Use in Advanced Breast Cancer (Second-line Treatment)

Research included Randomized Comparative Trials that was evaluated in Aromazin against other established hormonal agents. The populations studies explored were postmenopausal women with hormone-receptor positive locally advanced or metastatic breast cancer whose disease had progressed following prior anti-estrogen therapy. The key outcomes studies monitored included Overall Response Rate (ORR) (objective tumor size changes), Time to Progression (TTP), and Overall Survival (OS).

Comparative trials reported that measurements of Overall Response Rate (ORR) data show patterns related to comparability between Aromazin and the comparator. Some studies described patterns such as differences in median Time to Progression (TTP) measurements between the Aromazin treatment group and the comparator.

---

What Remains Uncertain and Areas for Future Research

The certainty surrounding final Overall Survival outcomes remains low or data are still emerging due to the need for prolonged follow-up and statistical complexity. Data for certain groups remain insufficient (e.g., specific age groups or those with severe organ impairment) and comparative evidence is lacking for certain combination regimens. The research highlights changes measured during the study period but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References TEXT and SOFT Trials: Exemestane with Ovarian Suppression in Premenopausal Women with Endocrine-Responsive Breast Cancer

Common questions about Aromazin (FAQ)

Q: Is it normal to feel tired when starting Aromazin?

A: Regulatory documents state that fatigue is listed as a very common side effect of Aromazin. This means that fatigue may affect more than 1 in 10 patients who use the medicine, according to clinical data.

Q: Does Aromazin affect mood or energy levels?

A: Official product information indicates that the medicine may affect both mood and energy. Side effects such as fatigue and insomnia (difficulty sleeping) are commonly reported, and depression is also listed among the possible adverse reactions.

Q: Does Aromazin cause weight gain?

A: While a range of gastrointestinal issues are commonly listed, official product information indicates that an increase in weight has been reported as a possible side effect.

Q: What are the most commonly reported side effects of Aromazin?

A: According to official product information, the most common side effects (those affecting more than 1 in 10 patients) include hot flushes, fatigue, increased sweating, joint pain (arthralgia), headache, and insomnia.

Q: Are there any long-term effects associated with taking Aromazin?

A: Official warnings note that long-term use of the medicine may be associated with a reduction in Bone Mineral Density (BMD), which could increase the risk of bone fractures and osteoporosis. Additionally, an increased incidence of certain cardiac ischemic events has been reported in comparison studies.

Q: Is it true that Aromazin can affect bone density?

A: Yes, official labeling states that the medicine may reduce Bone Mineral Density (BMD), which can increase the risk of osteoporosis and bone fractures. For this reason, official guidance states that BMD assessment is recommended for women with or at risk of osteoporosis at the start of treatment.

Q: Can Aromazin cause hot flashes, and is that normal?

A: Yes, hot flushes are listed in regulatory documents as a very common side effect of Aromazin. This means the symptom is frequently reported, affecting more than 1 in 10 patients.

Q: Is the brand name Aromazin interchangeable with a generic version?

A: The active ingredient contained in the medicine is exemestane. Official drug agencies recognize exemestane as the established generic name for this substance.

Q: What if I experience a rare side effect mentioned in the leaflet?

A: Official safety information describes certain serious and rare risks, such as hepatitis or severe changes in blood cell counts. Official guidance notes that due to certain risks, regular monitoring of patients is part of the treatment regimen.

Q: What is the main difference between Aromazin and other similar treatments?

A: Aromazin is classified as a steroidal aromatase inhibitor, which structurally distinguishes it from non-steroidal inhibitors in the same drug class. It is also described as an irreversible, mechanism-based inhibitor that permanently inactivates the aromatase enzyme.

Q: Why is Aromazin sometimes prescribed for women after menopause?

A: The official indications for use are focused on postmenopausal women because in this group, the medicine is designed to block the conversion of other hormones into estrogen in peripheral tissues, which is the primary source of estrogen after menopause.

Q: What kind of studies support the use of Aromazin?

A: The regulatory approval for Aromazin is based on evidence from large-scale, international Randomized Controlled Trials (RCTs). These studies examined the drug's use in postmenopausal women with both early and advanced breast cancer.

Q: Can men use Aromazin?

A: The official indications for Aromazin use are exclusively defined for postmenopausal women with breast cancer. Regulatory documents do not provide official dosing or efficacy data for use in men.

Q: What is the maximum duration Aromazin is generally used for?

A: For the adjuvant treatment of early breast cancer, official guidelines state that treatment is typically intended to continue for a total of five consecutive years of hormonal therapy, or until the cancer returns.

Q: Is Aromazin a chemotherapy drug?

A: Aromazin is classified as an aromatase inhibitor, which is a type of hormonal therapy. It is not categorized as traditional cytotoxic chemotherapy.

Q: Are there different doses of Aromazin available?

A: The medicine is generally supplied as a 25 mg film-coated tablet. Official labeling also specifies a 50 mg dose when the medicine is used at the same time as certain other medicines known as CYP 3A4 inducers.

Q: Does Aromazin affect sleep patterns?

A: Insomnia (difficulty sleeping) is listed in official product information as a very common side effect, affecting more than 1 in 10 patients.

Q: Can Aromazin cause stomach issues or digestive problems?

A: Yes, regulatory documents list several gastrointestinal side effects. These common side effects include nausea, vomiting, abdominal pain, diarrhea, constipation, and indigestion (dyspepsia).

Q: What is the active ingredient in Aromazin?

A: The active ingredient in the medicine is exemestane. This is the substance that acts to irreversibly inhibit the aromatase enzyme.

Q: How is Aromazin different from aromatase inhibitors that are not steroids?

A: The medicine is classified as a steroidal aromatase inhibitor. Its mechanism of action is described as an irreversible, mechanism-based inhibitor of the aromatase enzyme.

Q: Do older adults react differently to Aromazin?

A: Official documents state that no dose adjustment is typically considered necessary for older adults, and studies to date have not demonstrated geriatric-specific problems requiring dose adjustment.

Q: Why do official documents mention the need for monitoring while on Aromazin?

A: Monitoring is recommended in official documents due to potential clinically significant risks. This includes monitoring for the reduction of Bone Mineral Density (BMD) and checking for possible elevations in liver enzymes.

Q: Is Aromazin used for conditions other than the main ones listed?

A: Official regulatory documents define the only approved uses as the adjuvant treatment of early breast cancer and the treatment of advanced breast cancer in postmenopausal women who have progressed on prior therapy.

Q: What is the half-life of Aromazin's active component?

A: The active component of Aromazin has an estimated terminal elimination half-life of approximately 24 hours. This measure relates to how long the substance stays in the body after administration.

Q: Can Aromazin affect cholesterol levels?

A: Official adverse event information lists an increase in hypercholesterolemia (high cholesterol levels) among the common side effects that may occur during treatment.

Q: Is Aromazin an oral medication or an injection?

A: Aromazin is an oral medication that is supplied as a film-coated tablet and is taken by mouth.

Q: Are there any warnings about driving or operating machinery while on Aromazin?

A: Official warnings advise that patients should not attempt to drive or operate machinery if they experience side effects like dizziness, somnolence (drowsiness), or fatigue.

Q: Why is the drug's purpose defined as 'adjuvant therapy' in some cases?

A: The term 'adjuvant therapy' is used when the medicine is given after initial treatment, such as surgery, to lower the chance of the cancer coming back. The medicine is intended to complement, or aid, the effect of the primary treatment.

Storage Conditions and Packaging

Aromasin (exemestane) tablets must be stored at a Controlled Room Temperature, defined as 25 C (77 F), with permitted temperature excursions between 15 C and 30 C (59 F and 86 F). The medicine's stability is maintained when it is kept within this prescribed temperature range.

The tablets should be kept in the original HDPE bottle and secured with the child-resistant screw cap.

Child Safety and Disposal

Aromasin must be stored out of the reach and sight of children.

Expired or unused tablets, including the container, must be disposed of in accordance with local, regional, and national regulations. To protect the environment, the medicine should not be released into wastewater systems or household garbage unless specifically authorized by local disposal guidelines.